Accreditation/Credit Designation

Medical College of Wisconsin

2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are sponsored by the Medical College of Wisconsin.

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The Medical College of Wisconsin designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Medical College of Wisconsin designates this activity for up to 1.00 hours participation for continuing education for allied health professionals.

Acknowledgment of Support

This activity is supported by an educational grant from Omeros.

Community Practice Connections™: Transplant-Associated Thrombotic Microangiopathy (TA-TMA): Integrating New Data to Improve Patient Outcomes

Release Date: April 28, 2021
Expiration Date: April 28, 2022

Activity Overview

This Community Practice Connections™ program provides an in-depth review of the treatment of transplant-associated thrombotic microangiopathy (TA–TMA). This unique and engaging multimedia activity is ideal for the community-based clinician, and provides guidance on the pathogenesis, diagnosis, differential diagnosis, current and emerging therapies, and advances in patient care associated with TA–TMA.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Omeros.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward hematologists, medical oncologists, researchers, and investigators who treat, or are interested in the treatment of hematologic malignancies. Other allied health care professionals, including nurse practitioners, physician assistants, and nurses involved in the treatment and management of patients with hematologic malignancies, will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review current diagnostic criteria for hematopoietic stem cell transplant (HSCT)–TMA and ways to differentiate it from other stem cell transplant–associated complications with overlapping symptoms
  • Assess the role of dysregulated complement activation in the pathogenesis of HSCT–TMA
  • Discuss the rationale concerning the application of complement-targeted therapies, including MASP-2 inhibitors, in the treatment of HSCT–TMA
  • Evaluate recent clinical trial data concerning the effectiveness of emerging therapies in the treatment of HSCT–TMA

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Faculty

Sergio A. Giralt, MD, FACP
Sergio A. Giralt, MD, FACP
Professor of Medicine
Weill Cornell Medical College
Melvin Berlin Family Chair in Multiple Myeloma
Deputy Head, Division of Hematologic Malignancies
Chief Attending Physician, Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Actinium Pharmaceuticals, Amgen, Bristol Myers Squibb, Celgene, Janssen, Pfizer, Sanofi; Other: Scientific Advisory Board: Actinium Pharmaceuticals, Amgen, Bristol Myers Squibb, Celgene, GSK, Janssen, Jazz Pharmaceuticals.

Christopher Dandoy, MD, MS
Christopher Dandoy, MD, MS
Assistant Professor of Clinical Pediatrics
Division of Bone Marrow Transplantation and Immune Deficiency
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Disclosures: Consultant: Omeros.

Sonata Jodele, MD
Sonata Jodele, MD
Research Professor of Pediatrics
Division of Bone Marrow Transplantation and Immune Deficiency
Cincinnati Children’s Hospital Medical Center
Cincinnati, Ohio

Disclosures: Grant Research Support: National Institutes of Health–funded R01 study (eculizumab supplied by Alexion at no charge to study subjects); Consultant: Omeros; Other: United States Patent No: US 10,815,296 B2.

Jeffrey Laurence, MD
Jeffrey Laurence, MD
Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant Research Support: Omeros; Consultant: Omeros.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By